BridgeBio Oncology Therapeutics, Inc. (BBOT) Balance Sheet
BBOT balance sheet, 2025
December 31, 2025 · U.S. dollars$448.4M assets = $37.3M liabilities + $411.1M equity
Both columns are drawn to the same scale: what BBOT owns equals what it owes plus shareholders’ equity. Hover a block for its value.
BBOT financial health
Descriptive bands, not a rating. Fiscal 2025.
BBOT balance sheet trends, 2021–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $144,2812021 | $448.4M2025 | +646.6%/yr | |
| Total liabilities | $162,6382021 | $37.3M2025 | +289.1%/yr | |
| Shareholders’ equity | −$18,3572021 | $411.1M2025 | — | |
| Cash & short-term investments | $250,0002023 | $425.5M2025 | +4,025.3%/yr | |
| Total debt | $36,9612021 | $2.8M2025 | +194.1%/yr | |
| Net cash (debt) | −$36,9612021 | $422.7M2025 | +$422.7M | |
| Working capital | $3.5M2023 | $390.4M2025 | +$386.9M | |
| Book value per share | −$0.002021 | $13.202025 | — | |
| Shares outstanding | 20.5M2021 | 31.1M2025 | +11.0%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BBOT assets
BBOT liabilities and equity
BBOT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
BBOT balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & short-term investments | $425.5M | $1.7M | $250,000 | — | — |
| Cash & equivalents | $373.7M | $1.7M | $250,000 | — | — |
| Short-term investments | $51.8M | $124.8M | $0 | — | — |
| Receivables | $386,000 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $0 | $252,000 | $3.7M | — | — |
| Total current assets | $425.5M | $1.9M | $3.9M | — | — |
| Property, plant & equipment (net) | $3.3M | $490,000 | $596,000 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $19.6M | $192.0M | $0 | $144,578 | $144,281 |
| Total assets | $448.4M | $194.4M | $332,894 | $144,578 | $144,281 |
| Liabilities | |||||
| Accounts payable | $1.4M | $3.1M | $575,000 | — | — |
| Short-term debt | $522,000 | — | $70,095 | $43,106 | $36,961 |
| Total current liabilities | $35.0M | $187,515 | $396,463 | $166,455 | $162,638 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $2.8M | $0 | — | — | — |
| Other long-term liabilities | $2.2M | $5.5M | $104.8M | $0 | $0 |
| Total liabilities | $37.3M | $5.7M | $396,463 | $166,455 | $162,638 |
| Shareholders' equity | |||||
| Common stock & paid-in capital | $8,000 | $192.4M | $460 | $288 | $288 |
| Retained earnings (deficit) | −$356.6M | −$3.7M | −$88,569 | −$46,877 | −$43,357 |
| Accumulated other comprehensive income | $16,000 | — | — | — | — |
| Total shareholders' equity | $411.1M | $188.7M | −$63,569 | −$21,877 | −$18,357 |
| Key figures | |||||
| Total debt | $2.8M | — | $70,095 | $43,106 | $36,961 |
| Net cash (debt) | $422.7M | — | $179,905 | −$43,106 | −$36,961 |
| Working capital | $390.4M | $1.8M | $3.5M | — | — |
| Tangible book value | $411.1M | $188.7M | −$63,569 | −$21,877 | −$18,357 |
| Book value per share | $13.20 | — | −$0.00 | −$0.00 | −$0.00 |
| Shares outstanding | 31.1M | — | 20.5M | 20.5M | 20.5M |
| Current ratio | 12.14 | 10.40 | 9.93 | — | — |
| Quick ratio | 12.15 | 9.05 | 0.63 | 0.00 | 0.00 |
| Debt / equity | 0.01 | — | — | — | — |
| Equity / assets | 91.7% | 97.1% | −19.1% | −15.1% | −12.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $225.7M | $252.3M | $425.5M | $468.3M | $131.4M | $135.7M | $1.7M | $1.8M | $1.8M | $1.8M | — | — |
| Cash & equivalents | $54.1M | $52.7M | $373.7M | $408.7M | $31.5M | $26.2M | $1.7M | $1.8M | $1.8M | $1.8M | — | — |
| Short-term investments | $171.6M | $199.6M | $51.8M | $59.5M | $99.9M | $109.5M | $124.8M | — | — | — | — | — |
| Receivables | $0 | $146,000 | $386,000 | $226,000 | $1.1M | $40,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $16.7M | $14.1M | $0 | $7.5M | $9.9M | $5.6M | $252,000 | $256,166 | $261,147 | $266,123 | — | — |
| Total current assets | $242.4M | $266.5M | $425.5M | $476.0M | $142.3M | $141.3M | $1.9M | $2.0M | $2.1M | $2.1M | — | — |
| Property, plant & equipment (net) | $3.0M | $3.2M | $3.3M | $3.3M | $3.4M | $3.4M | $490,000 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $118.4M | $136.6M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $12.9M | $11.4M | $19.6M | $5.5M | $5.5M | $5.1M | $192.0M | $190.3M | $187.8M | $185.4M | $332,894 | $144,578 |
| Total assets | $376.7M | $417.6M | $448.4M | $484.8M | $151.3M | $149.8M | $194.4M | $192.3M | $189.9M | $187.5M | $332,894 | $144,578 |
| Liabilities | ||||||||||||
| Accounts payable | $6.7M | $12.1M | $1.4M | $3.6M | $2.2M | $3.7M | $3.1M | — | — | — | — | — |
| Short-term debt | $554,000 | $538,000 | $522,000 | $506,000 | $320,000 | $6,000 | — | — | — | — | $70,095 | $43,403 |
| Total current liabilities | $51.6M | $43.3M | $35.0M | $35.7M | $27.3M | $24.1M | $187,515 | $126,690 | $79,141 | $23,333 | $396,463 | $166,455 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $2.5M | $2.6M | $2.8M | $2.9M | $2.8M | $2.6M | $0 | — | — | — | — | — |
| Other long-term liabilities | $2.0M | $2.1M | $2.2M | $2.4M | $351.7M | $325.8M | $5.5M | $5.5M | $5.5M | $5.5M | $0 | $0 |
| Total liabilities | $53.6M | $45.4M | $37.3M | $38.1M | $379.0M | $349.9M | $5.7M | $5.6M | $5.6M | $5.5M | $396,463 | $166,455 |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $8,000 | $8,000 | $8,000 | $8,000 | $196.5M | $194.4M | $192.4M | $190.2M | $187.6M | $185.2M | $460 | $288 |
| Retained earnings (deficit) | −$455.1M | −$398.7M | −$356.6M | −$317.8M | −$273.0M | −$244.6M | −$3.7M | −$3.5M | −$3.4M | −$3.2M | −$88,569 | −$46,877 |
| Accumulated other comprehensive income | −$959,000 | −$981,000 | $16,000 | $36,000 | $51,000 | $191,000 | — | — | — | — | — | — |
| Total shareholders' equity | $323.1M | $372.3M | $411.1M | $446.7M | −$227.7M | −$200.0M | $188.7M | $186.7M | $184.3M | $182.0M | −$63,569 | −$21,877 |
| Key figures | ||||||||||||
| Total debt | $2.5M | $2.6M | $2.8M | $2.9M | $2.8M | $2.6M | — | — | — | — | $70,095 | $43,403 |
| Net cash (debt) | $223.2M | $249.6M | $422.7M | $465.4M | $128.6M | $133.1M | — | — | — | — | −$70,095 | −$43,403 |
| Working capital | $190.7M | $223.2M | $390.4M | $440.3M | $115.1M | $117.3M | $1.8M | $1.9M | $2.0M | $2.1M | — | — |
| Tangible book value | $323.1M | $372.3M | $411.1M | $446.7M | −$227.7M | −$200.0M | $188.7M | $186.7M | $184.3M | $182.0M | −$63,569 | −$21,877 |
| Book value per share | — | — | $5.14 | $10.27 | — | — | — | $7.94 | $7.84 | $7.74 | −$0.00 | −$0.00 |
| Shares outstanding | — | — | 80.0M | 43.5M | — | — | — | 23.5M | 23.5M | 23.5M | 20.5M | 20.0M |
| Current ratio | 4.69 | 6.16 | 12.14 | 13.33 | 5.22 | 5.87 | 10.40 | 16.12 | 26.23 | 90.42 | — | — |
| Quick ratio | 4.37 | 5.83 | 12.15 | 13.12 | 4.86 | 5.64 | 9.05 | 14.09 | 22.93 | 79.01 | 0.00 | 0.00 |
| Debt / equity | 0.01 | 0.01 | 0.01 | 0.01 | — | — | — | — | — | — | — | — |
| Equity / assets | 85.8% | 89.1% | 91.7% | 92.1% | −150.6% | −133.5% | 97.1% | 97.1% | 97.1% | 97.0% | −19.1% | −15.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 5, 2026); data from EODHD.
BBOT financial position
At the end of fiscal 2025 (December 31, 2025), BridgeBio Oncology Therapeutics had total assets of $448.4 million (up 130.6% from a year earlier), total liabilities of $37.3 million and shareholders' equity of $411.1 million. It held $425.5 million in cash and short-term investments against $2.8 million of debt, a net cash position of $422.7 million. Its current ratio was 12.14. In the latest quarter (ended June 30, 2026) total assets were $376.7 million and equity $323.1 million.
Related: BBOT income statement, BBOT cash flow statement, BBOT key metrics. See the BBOT stock overview for the latest quote and news.
BBOT balance sheet FAQ
What are BridgeBio Oncology Therapeutics's total assets?
BridgeBio Oncology Therapeutics reported total assets of $448.4 million at the end of fiscal 2025 (December 31, 2025), compared with $194.4 million a year earlier.
How much debt does BridgeBio Oncology Therapeutics have?
BridgeBio Oncology Therapeutics had $2.8 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.01.
How much cash does BridgeBio Oncology Therapeutics have?
BridgeBio Oncology Therapeutics held $425.5 million in cash and short-term investments at the end of fiscal 2025; with $2.8 million of debt that is net cash of $422.7 million.
What is BridgeBio Oncology Therapeutics's book value?
BridgeBio Oncology Therapeutics's shareholders' equity (book value) was $411.1 million at the end of fiscal 2025, or $13.20 per share.
What is BridgeBio Oncology Therapeutics's current ratio?
BridgeBio Oncology Therapeutics had current assets of $425.5 million and current liabilities of $35.0 million, a current ratio of 12.14 (it can cover its short-term obligations).